multi-kinase inhibitor (VEGFR) · small molecule
sunitinib
0 active trials across 4 of our biomarkers, targeting VEGFR/PDGFR/KIT. Not approved for any biomarker on marked.bio yet.
Also known as SU11248, Sutent.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| FGFR2 fusion or rearrangement | 0 | 1 | – |
| FGFR3 alteration (mutation or fusion) | 0 | 1 | – |
| FLT3 mutation (ITD/TKD) | 0 | 1 | – |
| RET fusion or mutation | 0 | 3 | – |
Trials
0 of 4 trials shown
-
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
RET fusion positive or FGFR2 fusion/other FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has p…
FGFR3 alteration (mutation or fusion)RET fusion or mutationFGFR2 fusion or rearrangementRefractory Solid Tumors
-
Sunitinib in Never-Smokers With Lung Adenocarcinoma
Must have \< 100 cigarettes smoked lifetime OR known to harbor a RET rearrangement OR another potentially targetable genomic alteration as defined per protocol
RET fusion or mutationLung Cancer
-
Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
Patients must have FLT3 mutated AML, either ITD or kinase domain mutations
FLT3 mutation (ITD/TKD)Acute Myeloid Leukemia
-
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
RET fusion positive,FGFR amplification, Refractory Solid Tumors that has recurred or progressed foll…
RET fusion or mutationRefractory Solid Tumors
No trials match these filters.